Michael N. Neely, MD

Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on antiviral, antiretroviral and antifungal compounds, he has experience with other therapeutic areas. He is currently board certified in Pediatrics and Pediatric Infectious Diseases, and he is the co-Director of the Laboratory of Applied Pharmacokinetics in the University of Southern California (USC) Keck School of Medicine, working with multidisciplinary faculty collaborators in the Departments of Pediatrics, Medicine, and Preventive Medicine, in the Schools of Pharmacy and Mathematics, and the Jet Propulsion Laboratory in Pasadena, CA. With expertise in computerized drug-response modeling, he is applying his research interests to the care of his patients by operating the first HIV therapeutic drug management service at LAC+USC, which is available to all HIV providers. He also provides out- and inpatient pharmacologic consultation for a wide range of therapeutically challenging cases. In the fall of 2010, he will complete a Master’s of Science program in Clinical and Biomedical Investigations at USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling, and he has recently been appointed to the United States Food and Drug Administration Anti-infective Drug Advisory Committee. He has received NIH funding for most of his post-doctoral career, is the author of numerous papers and abstracts, and he is invited to give talks and workshops on dose individualization and optimization worldwide.

• Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
  NIH · R01AI173238 · Jan 25, 2023 – Dec 31, 2027 · Role: Co-Investigator
• Precision Dosing for Critically Ill Children
  NIH · R01HD107687 · Aug 17, 2022 – Apr 30, 2026 · Role: Principal Investigator
• Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia
  NIH · R01AI158530 · Jul 11, 2022 – Jun 30, 2027 · Role: Co-Investigator
• Diagnosis and management of pediatric tracheostomy-associated infections
  NIH · R01HS027619 · Aug 1, 2021 – Jul 31, 2026 · Role: Co-Investigator
• OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core
  NIH · OT2HL161847 · May 24, 2021 – May 23, 2023 · Role: Co-Investigator
• PBPK and Population Modeling Seamlessly Linked to Clinical Trial Simulation in an Open-Source Software Platform
  NIH · U01FD006549 · Sep 1, 2018 – Aug 31, 2021 · Role: Principal Investigator
• Sequestration and deactivation of anthracycline by adipocytes in the leukemia microenvironment
  NIH · R01CA213129 · Aug 15, 2017 – Jul 31, 2022 · Role: Co-Investigator
• Ontogeny of Voriconazole Pharmaockinetics and Metabolism
  NIH · R01HD070886 · Feb 22, 2012 – Jan 31, 2019 · Role: Principal Investigator
• Plasma and Genital HIV Dynamics in Women
  NIH · K23AI076106 · Aug 15, 2007 – Aug 29, 2011 · Role: Principal Investigator
• Population Pharmacokinetic Modeling and Dual Optimal Control
  NIH · R01GM068968 · Jun 15, 2003 – Aug 31, 2017 · Role: Principal Investigator

• Klausner, Jeffrey
• Beringer, Paul
• Demetriades, Demetrios
• Terrault, Norah
• Luna, Brian
• Simon, Tamara